The FDA has approved a new therapy for the rare muscle wasting disease Duchenne muscular dystrophy (DMD) as Japan’s NS Pharma takes on Sarepta and its controversially approved rival. NS Pharma ...
NS Pharma, a subsidiary of Nippon Shinyaku Co., announced that acceptance has been received by Capricor Therapeutics (CAPR) from the U.S. FDA ...
Like Sarepta’s Vyondys 53 (golodirsen), NS Pharma’s drug – called viltolarsen – is a therapy designed to treat patients with DMD amenable to exon 53 skipping, a group that can currently ...
PARAMUS, N.J., March 10, 2025 /PRNewswire/ -- NS Pharma, Inc. (NS Pharma), a subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku), announced today that ...
India's Sun Pharmaceutical Industries said on Monday it will acquire Checkpoint Therapeutics , a U.S.-based immunotherapy and targeted oncology company, for $355 million.
10d
Hosted on MSNQNRX: More Positive Data Supporting Efficacy of QRX003 for NS; Campaign to Raise Awareness of the DiseaseQNRX READ THE FULL QNRX RESEARCH REPORT Positive interim clinical data Quoin Pharmaceuticals (NASDAQ:QNRX) is a clinical stage, specialty pharmaceutical company that focuses on developing treatments ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results